- Home
- HTH vs ABSI Comparison
HTH vs ABSI Comparison
Compare HTH & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | ABSI |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HTH | ABSI |
|---|---|---|
| Price | $36.54 | $10.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $41.00 | $14.40 |
| AVG Volume (30 Days) | 299.0K | ★ 4.0M |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 51.72 | 10.64 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $152,188,000.00 | $4,534,000.00 |
| Revenue This Year | $2.13 | $39.03 |
| Revenue Next Year | $2.14 | $310.91 |
| P/E Ratio | $28.88 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $30.78 | $2.24 |
| 52 Week High | $40.41 | $12.06 |
Technical Indicators
Market Signals| Indicator | HTH | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 32.74 | 53.35 |
| Support Level | $36.32 | $9.25 |
| Resistance Level | $38.52 | $11.66 |
| Average True Range (ATR) | 0.66 | 0.90 |
| MACD | -0.18 | -0.08 |
| Stochastic Oscillator | 12.34 | 44.64 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.